about
sameAs
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factorsGenome-wide association studies identify four ER negative-specific breast cancer risk lociGenome-wide association study identifies novel breast cancer susceptibility lociExome sequencing identifies MAX mutations as a cause of hereditary pheochromocytomaLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSA candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMSEffect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic studyGenome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathyCommon variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcomaLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.The GoldenGate genotyping assay: custom design, processing, and data analysis.Evaluating HapMap SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes.Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.Mouse genome-wide association mapping needs linkage analysis to avoid false-positive Loci.Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysisGenetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis.Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analysesVariation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia riskCommon non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association ConsortiumSingle nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph.Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.Oxidative stress in susceptibility to breast cancer: study in Spanish population.Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors.Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.Genetics of pheochromocytoma and paraganglioma in Spanish patients.Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.Exome sequencing of three cases of familial exceptional longevity.Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia.Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk.Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer riskInherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Genetic predisposition to in situ and invasive lobular carcinoma of the breast.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.
P50
Q21092455-D1BD759C-0F2B-4821-947E-15A0878D04B2Q24622610-9191C1B7-5295-4451-942A-2CB0421C2DF5Q24645441-E31CF861-8DA1-412C-B662-60BBA8909D40Q28241168-CDE51157-D0C2-49AB-AB96-4051688855AFQ28267893-D9CE9562-7FD8-4C2B-BE63-F122CA9301BFQ28388497-F33400C2-D2E9-47DC-B234-3261A37744CCQ28584533-8B5B8CBE-1B3A-4411-8C73-187F2E85407EQ28652720-C75E8795-13BF-4C0C-BB30-645239E94FF4Q28744127-A617F11E-FF52-4217-A517-E7621C8BF289Q28943314-84B8201F-192A-4D30-BC21-9FF17F03952DQ29028729-D0E168F7-9B9E-438A-8620-6980838183D7Q29416989-9CD90C46-6830-4472-892F-6DECFD0DAB75Q30653232-2AD77011-5603-4637-90D2-BCD2D598AE73Q33228354-1DA74190-D449-49CF-BE0D-430051E4B88CQ33296082-107A3817-F6B0-416C-9472-784940FED5BBQ33330850-74A21E79-32C9-40B1-B6E3-A7B7F42FC773Q33398543-C7E542D1-9392-4617-8B94-E27A8122E6F9Q33419870-9AAE436D-FB1E-4CD9-80E9-1A6EA99F2375Q33599595-1BD8729F-8236-4FEA-85C0-41E885813D7FQ33825180-BCB58DD2-F5A6-4381-AC92-5A88FEEDB48CQ34114297-A9528834-25EF-4E72-ACF9-06F478572AD4Q34379032-3E98A7CD-DE3E-4503-89AF-B965C1D0A44DQ34543075-BD5CC694-D3B4-4D5E-9002-9A33E65930A7Q34586198-DC5885D5-1F58-4409-BC69-146170E3A343Q34610274-ECA58724-5537-47FA-9086-A01EE6C462D5Q34797430-E84E9707-EC7F-43DC-8A1B-0D10577D5B5FQ34898735-E642AE50-7404-4F8D-8C34-E932FF0B8015Q34903062-DA1AA7A5-21E6-461F-B13B-D3CCE8824909Q34955974-71E1C266-1109-4774-A591-47A6F7AA8A3CQ35064451-0BD13DB3-9892-4D6A-8474-A001FB3A7FFBQ35080576-2C4BF4A9-8B60-467D-AB10-2F374728A2F7Q35082533-F5813FF4-7C62-409F-958A-1C0D74C7F0D8Q35082606-B636F06B-1D5D-4986-9C50-2A74DA8AECB5Q35102646-B7201EA9-9AA2-471E-B1CA-2D86B4F3F092Q35104068-F28D84FC-88DE-4AA3-ACBB-F5AF80E26F51Q35109800-24EE7659-605B-488E-9C63-C6FFD0ADAB62Q35151684-2DF8D946-A22A-4A93-A65C-E0C4E4497A7EQ35155449-0AC72B16-9600-43A4-9EBF-9166DF34CE49Q35179897-EAE4ADCC-16C5-45EA-9086-29356301EB20Q35524465-DF0CFEBB-F5E9-4A69-B548-88DAFA148A3C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anna González-Neira
@ast
Anna González-Neira
@en
Anna González-Neira
@es
Anna González-Neira
@nl
Anna González-Neira
@sl
type
label
Anna González-Neira
@ast
Anna González-Neira
@en
Anna González-Neira
@es
Anna González-Neira
@nl
Anna González-Neira
@sl
altLabel
Anna Gonzalez-Neira
@ast
Anna Gonzalez-Neira
@en
Anna Gonzalez-Neira
@es
Anna Gonzalez-Neira
@nl
Anna Gonzalez-Neira
@sl
prefLabel
Anna González-Neira
@ast
Anna González-Neira
@en
Anna González-Neira
@es
Anna González-Neira
@nl
Anna González-Neira
@sl
P1053
C-5791-2015
P106
P21
P31
P496
0000-0002-5421-2020